<DOC>
	<DOCNO>NCT00365456</DOCNO>
	<brief_summary>The objective show superior efficacy PTH ( 1-84 ) risedronate treat osteoporotic woman 12 month previously treat PTH ( 1-84 ) 12 month follow 12 month treatment risedronate .</brief_summary>
	<brief_title>Sequential Treatment Postmenopausal Women With Primary Osteoporosis ( FP-001-IM )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Women age 50 year diagnosis postmenopausal primary osteoporosis may enrol trial follow inclusion/exclusion criterion apply . All inclusion criterion must answer `` yes '' subject enrol trial . 1 . Has subject give informed consent accord local requirement trial related activity ? ( A trial related activity procedure would perform routine management subject ) . 2 . Is subject 50 year old ? 3 . Is subject postmenopausal ( 5 year ) judgement investigator ? 4 . Does subject primary osteoporosis lumbar spine T score &lt; 3.0 SD ( lumbar spine L1L4 , minimum two evaluable vertebra ) ? 5 . Does subject life expectancy &gt; 3 year ? 6 . Is subject able selfinject PTH ( 184 ) , ( PTH ( 184 ) injection helper ) ?</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Lumbar Spine Bone Mineral Density ( BMD )</keyword>
</DOC>